Skip to Content

Vonvendi Approval History

  • FDA approved: Yes (First approved December 8th, 2015)
  • Brand name: Vonvendi
  • Generic name: von willebrand factor (recombinant)
  • Dosage form: for Injection
  • Company: Baxalta Incorporated
  • Treatment for: von Willebrand's Disease

Vonvendi [von Willebrand factor (recombinant)] is a recombinant von Willebrand factor (VWF) indicated for on-demand treatment and control of bleeding episodes in adults diagnosed with von Willebrand disease.

Development History and FDA Approval Process for Vonvendi

Apr 17, 2018Approval FDA Approves Vonvendi [von Willebrand factor (recombinant)] for Perioperative Management of Bleeding in Adult Patients with von Willebrand Disease
Dec  8, 2015Approval FDA Approves Vonvendi (Von Willebrand Factor (Recombinant)) to Treat Bleeding Episodes in Patients with VWD

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.